Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dr Reddys Laboratories (RDY) Equity Income (2016 - 2025)

Historic Equity Income for Dr Reddys Laboratories (RDY) over the last 15 years, with Q4 2025 value amounting to $258268.3.

  • Dr Reddys Laboratories' Equity Income fell 4808.0% to $258268.3 in Q4 2025 from the same period last year, while for Dec 2025 it was -$4.9 million, marking a year-over-year decrease of 8705.2%. This contributed to the annual value of -$2.6 million for FY2025, which is 4458.17% down from last year.
  • Dr Reddys Laboratories' Equity Income amounted to $258268.3 in Q4 2025, which was down 4808.0% from -$722102.8 recorded in Q3 2025.
  • Dr Reddys Laboratories' 5-year Equity Income high stood at $2.0 million for Q2 2022, and its period low was -$4.4 million during Q1 2025.
  • Its 5-year average for Equity Income is -$881593.3, with a median of -$861051.4 in 2021.
  • Its Equity Income has fluctuated over the past 5 years, first soared by 5080744222.96% in 2023, then crashed by 21187.61% in 2024.
  • Quarter analysis of 5 years shows Dr Reddys Laboratories' Equity Income stood at -$1.0 million in 2021, then changed by 0.0% to -$1.0 million in 2022, then soared by 132.43% to $324267.2 in 2023, then soared by 53.4% to $497435.0 in 2024, then plummeted by 48.08% to $258268.3 in 2025.
  • Its Equity Income was $258268.3 in Q4 2025, compared to -$722102.8 in Q3 2025 and -$23369.4 in Q2 2025.